A COST-EFFECTIVENESS ANALYSIS OF ADJUVANT PEMBROLIZUMAB IN THE TREATMENT OF PATIENTS WITH EARLY-STAGE (STAGES IB-III) NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING COMPLETE RESECTION AND PLATINUM-BASED CHEMOTHERAPY

被引：0
|
作者：
Draganigos, A. [1 ]
Nguyen, S. [1 ]
Skroumpelos, A. [2 ]
Iliopoulou, E. [2 ]
Mylonas, C. [2 ]
Karokis, A. [2 ]
机构：
[1] MSD Greece, Athens A1, Greece
[2] MSD Greece, Alimos, Attica, Greece
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE192
引用
收藏
页码：S92 / S92
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF DURVALUMAB AFTER CHEMORADIATION IN STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)
    Criss, S. D.
    Mooradian, M. J.
    Lumish, M. A.
    Reynolds, K. L.
    Kong, C. Y.
    VALUE IN HEALTH, 2018, 21 : S12 - S12
  • [22] The Role of Adjuvant Chemotherapy in Patients With Stage IB Non-Small Cell Lung Cancer
    Yang, L.
    Li, B.
    Xu, Y.
    Zou, B.
    Fan, B.
    Qin, W.
    Fan, X.
    Zhang, D.
    Wang, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E459 - E459
  • [23] Cost-effectiveness analysis of pembrolizumab with chemotherapy for metastatic nonsquamous non-small cell lung cancer in Taiwan
    Lee, Wei-Ling
    Chou, Wan-Hsuan
    Chang, Wei-Pin
    Chang, Tsung-Wei
    Kuo, Chun-Nan
    Chang, Wei-Chiao
    JOURNAL OF FOOD AND DRUG ANALYSIS, 2024, 32 (04)
  • [24] Is the platinum-based chemotherapy necessary for elderly patients with advanced non-small cell lung cancer (NSCLC)?
    Daga, H.
    Takeda, K.
    Kiyota, H.
    Tokunaga, S.
    Nanjo, S.
    Sumitani, M.
    Shoji, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] A REVIEW OF COST-EFFECTIVENESS STUDIES OF PEMBROLIZUMAB FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
    Qiao, N.
    Insinga, R.
    Burke, T.
    Lopes, G.
    VALUE IN HEALTH, 2020, 23 : S41 - S42
  • [26] International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung Cancer
    Kareff, Samuel A.
    Han, Sunwoo
    Haaland, Benjamin
    Jani, Chinmay J.
    Kohli, Rhea
    Aguiar Jr, Pedro Nazareth
    Huang, Yiqing
    Soo, Ross A.
    Rodriguez-Perez, Angel
    Garcia-Foncillas, Jesus
    Domine, Manuel
    de Lima Lopes, Gilberto
    JAMA NETWORK OPEN, 2024, 7 (05) : E2413938
  • [27] Pembrolizumab in Combination With Platinum-Based Chemotherapy in Recurrent EGFR/ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
    Gadgeel, S.
    Dziubek, K.
    Nagasaka, M.
    Braun, T.
    Hassan, K.
    Cheng, H.
    Wozniak, A.
    Halmos, B.
    Stevenson, J.
    Patil, P.
    Pennell, N.
    Fidler, M. J.
    Bonomi, P.
    Qin, A.
    Niu, Z.
    Nagrath, S.
    Kalemkerian, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S863 - S863
  • [28] Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC)
    Liang, Ying
    Wakelee, Heather A.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2013, 2 (05) : 403 - 410
  • [29] Should Patients with Stage IB Non-Small Cell Lung Cancer Receive Adjuvant Chemotherapy?
    Wang, J.
    Nan, W.
    Lv, C.
    Yan, S.
    Yang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S849 - S849
  • [30] Cost-effectiveness of first-line pembrolizumab plus chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC).
    Kim, Ashley
    Devine, Beth
    Roth, Joshua A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345